Magnetic resonance radiation therapy with Elekta Unity is now in clinical use at The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital
“As a player on the international forefront of cancer care and research, we became a member of the Elekta MR-linac consortium because we believed that real-time, high-field imaging during radiation delivery would transform cancer care and enable new treatment regimens that offer patients improved safety and efficacy,” said Marlies Nowee, Radiation Oncologist, at NKI-AvL. “Elekta Unity is now a reality, and we are excited to start treating our patients. The ability to see what we treat in real time and adapt treatment on a daily basis enables unprecedented precision and ensures that each patient receives the right dose, delivered to the right location, at every treatment session. We are proud to have played a role in bringing Elekta Unity into clinical use.”
NKI-AvL, which is a founding member of Elekta’s MR-linac Consortium, recently started treating its first patient using Elekta Unity. The patient is receiving treatment for prostate cancer. The Elekta MR-linac Consortium is a collaborative industrial-academic partnership that Elekta founded with seven centers and our technology partner, Philips in 2012 to provide an evidence-based introduction of the MR-linac to the medical community, and to support the advancement of the technology.
“The NKI-AvL team made critical contributions to developing the technological innovations that allow Elekta Unity to perform as no other radiation delivery system can, and we are gratified to see their patients reaping the rewards of their efforts,” said Richard Hausmann, Elekta President and CEO. “NKI-AvL is the second cancer center in Europe to offer MR/RT with Elekta Unity to their patients, and additional centers will be clinically implementing this personalized, precision cancer therapy in the weeks and months ahead. The strong enthusiasm for this technology within the radiation oncology community reflects its truly novel capabilities and ease with which it can be incorporated into routine clinical workflows.”
To learn more, visit elekta.com/Unity.
Elekta Unity is pending 510(k) pre-market clearance and not available for commercial distribution or sale in the U.S.
# # #
For further information, please contact:
Oskar Bosson, Global EVP Corporate Communications and Investor Relations
Tel: +46 70 410 7180, e-mail: Oskar.Bosson@elekta.com
Time zone: CET: Central European Time
Raven Canzeri, Global Public Relations Manager
Tel: +1 770 670 2524, e-mail: Raven.Canzeri@elekta.com
Time zone: ET: Eastern Time
About Elekta
Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com.
